Global

A look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA

The long planned for transparency of industry payments to doctors, pharmacists, nurses and others has shone some dappled light on the UK industry, writes Leela Barham.

Dave Handelsman offers a smart approach to dealing with the EMA's new guidelines on the anonymization of clinical trial data.

The UK's Brexit vote has unleashed turbulence in Europe - not least on its pharma sector. Reflector reports.

Leela Barham looks at the implications for the UK industry in the aftermath of last week's vote for Brexit.

Only one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports.

The UK vote suddenly puts industry on a turbulent track in Europe. The many challenges and effects are outlined here.

With one of the oldest populations in the world, Italy faces a daunting question: how can it protect its universal healthcare system while maintaining the country’s high quality standards for public healthcare and ensuring its survival for the next generation? Up to the challenge, Italy must now learn to do more with less.

Companies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.

EU and UK industry groups did their best to display calm and confidence as the world woke up to the reality of Brexit.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.

Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.

Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision – despite the decades-old EU taboo about linking pricing with authorizations.

NHS England head Simon Stevens believes the UK's PPRS needs significantly updating.

Eleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.

While the Italian fashion and automotive industries may steal the global thunder, another sector in Italy flourishes beneath the public’s radar. The country’s pharmaceutical industry continues to punche above its weight in many areas and has supported Italy’s national economy through many periods of weakness.

We desperately need new anti-infective drugs to avoid life threatening infections. Let’s make that happen by punishing companies who don’t invest in R&D for these specific drugs.

Is a more "light-touch" appraisal process the key to getting the UK's NICE to do more with less? Leela Barham reports.

European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs. Pharm Exec looks at how the industry is preparing for this historic moment.

The dilemma continues: Which medicines should Europe's health systems pay for – and how much should they pay?

As companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.

while France remains a global force in the pharmaceutical, medical device, and vaccines fields-and continues to tout a solid manufacturing base and re-exportation culture-questions are arising over the long- term sustainability of the country’s healthcare system and its traditionally generous public health provisions.

Reflector sees both altruism and self-interest in European thinking on neglected diseases.

Egypt is not just a sun-soaked paradise defined by pyramids and tombs, or-alternatively-a hotbed for political turmoil and revolution. It’s also a vibrant and growing market for pharmaceuticals, experts contend.

Deep in the massive bureaucracy of the United Nations is an undertaking that appears to have been conceived and designed to be combative - and biopharma may be the target. Stephen Tepp reports.

March 21, 2016

NICE's notion to charge the industry for its technology appraisals looks set to become reality, writes Leela Barham.

Elvis Pacela asks why the prospect of harmonized content is so challenging, and what can pharma companies learn from other sectors about more optimal, modern ways of working and sharing data?

A new wave of technologies supported by innovative business models is transforming the vaccine landscape - and raising the bar on performance. As the demand for cures for chronic diseases accelerates, and with more global outbreaks of viral diseases like Zika and Ebola a virtual certainty, solutions can’t come soon enough.

A new study spells out the many drug pricing problems in Europe just fine, but fails to address a central access issue-leaving its recommendations frustratingly limited for industry and policymakers.